Long‐Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats
Background The long‐term effects of dipeptidyl peptidase 4 (DPP4) inhibitors on blood pressure and cardiovascular and renal health remain controversial. Herein, we investigated the extended (>182 days) effects of DPP4 inhibition in a model of spontaneous hypertension, heart failure, diabetes mell...
Main Authors: | Edwin K. Jackson, Zaichuan Mi, Delbert G. Gillespie, Dongmei Cheng, Stevan P. Tofovic |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.020088 |
Similar Items
-
Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al. -
Progress on application of dipeptidyl peptidase Ⅲ in the treatment of sepsis
by: WANG Yingchen, SUN Liqun
Published: (2023-01-01) -
The Long-Term Study of Urinary Biomarkers of Renal Injury in Spontaneously Hypertensive Rats
by: Sebastián Montoro-Molina, et al.
Published: (2021-07-01) -
Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
by: Sunghwan Suh, et al.
Published: (2015-06-01) -
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
by: Jie Huang, et al.
Published: (2022-03-01)